|Bid||0.00 x 1100|
|Ask||0.00 x 1000|
|Day's Range||25.92 - 28.80|
|52 Week Range||19.38 - 74.10|
|Beta (5Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.00|
Upon first glance, Axsome Therapeutics (NASDAQ: AXSM) doesn't exactly sound like a candidate for being a safe stock that's ready to buy today. At present, the biotech has no approved drugs nor any revenue. Its drug AXS-05 is its flagship program, and it's being investigated in a late-stage clinical trial for its usefulness in treating agitation in Alzheimer's disease, as well as in another trial for smoking cessation.
Biotech is one of the fastest growing areas in healthcare, and one of the more exciting sectors in the stock market. Here's why three Fool.com contributors are bullish on 10x Genomics (NASDAQ: TXG), Axsome Therapeutics (NASDAQ: AXSM), and Doximity (NYSE: DOCS). 10x Genomics sells the machines and associated consumables that allow scientists to look in and around a single cell, referred to as spatial biology.
Insiders who bought US$374k worth of Axsome Therapeutics, Inc.'s ( NASDAQ:AXSM ) stock at an average buy price of...